Free Trial
NYSE:ANVS

Annovis Bio Q4 2024 Earnings Report

Annovis Bio logo
$2.34 -0.06 (-2.50%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$2.39 +0.05 (+2.14%)
As of 05/30/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$0.43

Annovis Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annovis Bio Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Friday, March 21, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Annovis Bio's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Annovis Bio Earnings Headlines

Missed Nvidia? Trump’s Trade War Could Create a Bigger Winner
Missed out on Nvidia? Don’t worry — a bigger AI opportunity may be emerging right now, thanks to Trump’s newly announced tariffs. One under-the-radar U.S. semiconductor stock just gained a major edge over its foreign rivals. With demand poised to skyrocket, this chipmaker could be perfectly positioned to ride the next wave of AI growth. Shares are still flying low — but not for long.
See More Annovis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email.

About Annovis Bio

Annovis Bio (NYSE:ANVS), a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

View Annovis Bio Profile

More Earnings Resources from MarketBeat